Article

Study: doxycycline better for dry eye than placebo

Laguna Hills, CA-The results of a phase II study show that Alacrity Biosciences' ALTY-0501 treats the symptoms of dry eye better than placebo.

Laguna Hills, CA-The results of a phase II study show that Alacrity Biosciences' ALTY-0501 treats the symptoms of dry eye better than placebo.

The study involved a double-masked, parallel group. One hundred sixty patients with dry eye disease randomly received ALTY-0501 eye drops or placebo eye drops four times daily for 56 days. The patients were exposed to a controlled adverse environment on days one, 28 and 56. Researchers measured environmental damage to the ocular surface by using fluorescein staining.

ALTY-0501 patients relative to placebo patients had statistically significantly lower scores for fluorescein staining of the total cornea after exposure to the control on day 28. In addition, ALTY-0501 produced differences as compared with placebo in total corneal and conjunctival staining, superior corneal staining and nasal conjunctival staining.

Patients who received ALTY-0501 also had significantly lower scores for the symptoms of burning, stinging, and grittiness, according to the patient diaries.

"We plan to discuss the phase II data and confirm our phase IIb/III strategy with the FDA in the fourth quarter of 2007," said David Power, the company's chief executive officer. "Our intent is that these discussions will allow us to initiate phase III clinical trials early in 2008 with a clear path for regulatory approval."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.